Literature DB >> 9278288

Mammalian cell expression of dimeric small immune proteins (SIP).

E Li1, A Pedraza, M Bestagno, S Mancardi, R Sanchez, O Burrone.   

Abstract

We have designed and expressed bivalent small immune proteins (SIP) based on scFv fragments connected through a short linker of four amino acids to the CH3 domain of the human immunoglobulin gamma 1 H-chain. Three different versions have been designed and expressed in mammalian cells. In one construct a cysteine residue was included in the last amino acid of the flexible 15-amino acid long linker connecting the V(L) and V(H) domains, thus creating a disulphide bond stabilized molecule. A version with a shorter (five amino acids) V(L)/V(H) linker was also produced and shown to be efficiently assembled and secreted. All three SIPs form dimers retaining their antigenic specificity in Western blotting and having a comparable functional affinity (avidity) as determined by ELISA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278288     DOI: 10.1093/protein/10.6.731

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  19 in total

1.  Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution.

Authors:  H T Zhang; J E Kacharmina; K Miyashiro; M I Greene; J Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.

Authors:  Elisa Ventura; Francesca Sassi; Sara Fossati; Arianna Parodi; William Blalock; Enrica Balza; Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Luciano Zardi
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

3.  Ubiquitin-Activated Interaction Traps (UBAITs) identify E3 ligase binding partners.

Authors:  Hazel F O'Connor; Nancy Lyon; Justin W Leung; Poonam Agarwal; Caleb D Swaim; Kyle M Miller; Jon M Huibregtse
Journal:  EMBO Rep       Date:  2015-10-27       Impact factor: 8.807

4.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

5.  Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.

Authors:  M Catucci; F Prete; M Bosticardo; M C Castiello; E Draghici; M Locci; M G Roncarolo; A Aiuti; F Benvenuti; A Villa
Journal:  Gene Ther       Date:  2011-12-22       Impact factor: 5.250

6.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.

Authors:  Roberto Di Niro; Federica Ziller; Fiorella Florian; Sergio Crovella; Marco Stebel; Marco Bestagno; Oscar Burrone; Andrew R M Bradbury; Paola Secco; Roberto Marzari; Daniele Sblattero
Journal:  BMC Biotechnol       Date:  2007-08-01       Impact factor: 2.563

7.  In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system.

Authors:  Andrea Predonzani; Francesca Arnoldi; Alejandro López-Requena; Oscar R Burrone
Journal:  BMC Biotechnol       Date:  2008-04-18       Impact factor: 2.563

8.  Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.

Authors:  Moitza Principe; Patrizia Ceruti; Neng-Yao Shih; Michelle S Chattaragada; Simona Rolla; Laura Conti; Marco Bestagno; Lorena Zentilin; Sheng-Hui Yang; Paola Migliorini; Paola Cappello; Oscar Burrone; Francesco Novelli
Journal:  Oncotarget       Date:  2015-05-10

9.  Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.

Authors:  Rémy Gébleux; Marco Stringhini; Ruben Casanova; Alex Soltermann; Dario Neri
Journal:  Int J Cancer       Date:  2016-12-30       Impact factor: 7.396

10.  Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.

Authors:  E El-Emir; J L J Dearling; A Huhalov; M P Robson; G Boxer; D Neri; G A M S van Dongen; E Trachsel; R H J Begent; R B Pedley
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.